Today's developments at SBI
Research grants and technologies
- Find out what's on the horizon for new products
SBI and Transposagen release PiggyBac Transposon VectorsInstant, reversible and inducible transgenesis.
Read PR Newswire Press Release-May 11th, 2011.
DV Biologics, System Biosciences Ink Stem Cell PartnershipRead June 14th, 2010 Press Release
Small Business Innovative Research Grants
- March 5, 2009:
SBI is pleased to announce the new SBIR Research Grant Award for Dr. Nandita Sarkar. The project entitled, "A system for identifying microRNAs that bind a target RNA", Grant 1R43GM087779-01, will develop and validate a genetic selection system for identification of microRNAs that functionally interact with RNAs of interest.
- December 4, 2008: SBI proudly announces the new SBIR Research Grant Award for Dr. Liansen Liu. The project entitled, "High-throughput identification of validated small transcriptional activation RNAs", Grant R43GM87116-01, is aimed at developing a method for generating small RNAs that specifically activate genes in mammalian cells.
- August 1, 2008: The National Institutes of Health grants a Phase I SBIR Grant award to Dr. Travis Antes. This new grant, entitled, "Permanent Knockdown of MicroRNAs using a Lentiviral-based Anti-miR System" (1 R43 GM085861-01) will support the development of technologies to inhibit microRNA function to investigate the roles of microRNA signaling in biological pathways.
- April 7, 2008: System Biosciences proudly announces the National Institutes of Health SBIR 2 year Grant award to Dr. Travis Antes. This new grant, entitled, "New methods for discovery and study of microRNAs and other small noncoding RNAs" (2 R44 GM077718-02A1) will enable the further invention and development of novel SBI technologies for the study of microRNAs.
- June 2, 2006: System Biosciences (SBI) announced that it has received 3 new SBIR grants—two phase I grants and one phase II grant. This brings to a total of 7 SBIR grants that SBI has received since its inception.
The focus of the two phase I SBIR grants was to develop methods to amplify mRNA sequences from small amount of tissue, and methods to identify the expression profile of anti-sense gene transcripts, respectively.
The focus of the phase II SBIR grant was on transcriptional reporter vectors and libraries and supports our research and development of novel vectors and libraries enabling genome-wide interrogation of gene transcription and expression.
Based in Mountain View, California, SBI is focused on developing novel and innovative tools and services to facilitate genome-wide functional screening, discovery, and analysis of genes/elements that regulate biological responses. SBI has launched pooled genome-wide siRNA libraries pre-packaged in lentiviral vectors that target the entire human or mouse genome. SBI also offers reagents for delivering lentiviral expression system, and kits for amplifying mRNAs and screening new micro RNAs.
- May 2, 2005: System Biosciences (SBI) announced that is offering the first small-interfering RNA (siRNA) libraries that target the entire human and mouse genomes. Each GeneNet™ siRNA Library contains more than a hundred thousand siRNA templates that target 47,400 human or 39,000 mouse transcripts. These libraries enable researchers to screen these organisms’ complete genomes, and identify genes whose function is regulating, controlling, or otherwise affecting specific biological processes, such as signaling cascades, apoptosis, cell proliferation, and differentiation. Genes discovered with this approach are candidates for novel drug targets or diagnostic biomarkers. “We believe that the cost-effective, ready-to-use siRNA library format and its compatibility with Affymetrix GeneChip® Arrays for data analysis make the GeneNet Libraries a very practical and useful tool in a wide range of research areas for our partners,” says Alex Chenchik, Vice President of R&D at SBI.
Concurrent with the launch, the GeneNet Libraries will be provided to a consortium of Japanese researchers organized by B-Bridge International, a collaborator of SBI. “The collaboration with the B-Bridge consortium will allow us to fast-track market adoption of our genome-wide libraries.” stated Enal Razvi, Head of Business Development at SBI.
The B-Bridge consortium consists of research labs from several leading institutes, including Osaka University, Nagoya University, the Japanese National Cancer Center, Tokyo Medical University, Ehime University, the Japanese Foundation for Cancer Research, the National Center for Geriatrics and Gerontology, and the National Institute for Advanced Industrial Sciences (AIST). Each laboratory involved in the consortium pursues different research interests but have partnered to share expertise, data, and techniques to maximally utilize the power for RNAi technology to more rapidly advance their research objectives. B-Bridge International facilitates and manages this exchange by providing research tools, analysis, and experimental data. According to Taka Mizutani, Director of Business Development for B-Bridge, “The SBI libraries will provides our network of researchers with unparalleled ability to analyze function and identify the sets of genes involved in various responses of interest. These libraries enable experiments that are just not possible with a simpler gene-by-gene knockdown approach.”
- August 23, 2004: System Biosciences (SBI) announced the launch of its Full Spectrum ™ RNA Amplification Kit which enables researchers to use real-time PCR to quantify expression levels of more than 125 different genes from small samples with limited numbers of cells.
Analysis of gene expression levels from pure but limited samples such as biopsies, cytology specimens, and microdissected tissues is essential to understand complex biological processes controlling processes such as the progression of disease, mechanisms of organism development, and responses to potential drugs or toxins. Current approaches to uniformly amplify the limited amount of RNA from these critical samples for this type of analysis are time-consuming and costly. The Full Spectrum RNA Amplification method is unique in that it provides an economical single-tube procedure that can be completed in just three hours.
Unlike other RNA amplification technology, the Full Spectrum method provides unbiased amplification of all regions of the expressed RNA. This feature enables researchers to detect any portion of the expressed sequence, which is an essential requirement to obtain expression data for the significant portion of genes that are expressed as more than one splice variant. Often different splice variants have different biological functions and are involved in separate responses.
The Full Spectrum procedure makes use of a specially developed universal primer that preferentially binds to messenger RNA transcripts and uniformly amplifies these gene transcripts using low-cycle PCR. This approach maintains the relative levels of each transcript species present in the starting samples, even when using starting amounts of RNA as low as 5 nanograms. As a result, an amplified pool of cDNA is produced that can be used as a template to quantify the levels of expressed genes in the original sample. This approach is more robust, faster, and requires fewer steps than other RNA amplification approaches. The Full Spectrum RNA Amplification product is the first of a series of products based on this novel universal primer approach.
SBI is based in Mountain View, California and focuses on developing tools and services to facilitate genome-wide functional screening, discovery, and analysis of genes that regulate biological responses.